<DOC>
	<DOC>NCT00954590</DOC>
	<brief_summary>The purpose of this study is to determine if Dimebon is safe and effective in patients with moderate to severe Alzheimer's disease.</brief_summary>
	<brief_title>A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>ModeratetoSevere Alzheimer's disease MiniMental State Examination (MMSE) Score between 5 to 14, inclusive Stable on donepezil for at least 6 months Other causes of dementia Major structural brain disease Unstable medical condition or significant hepatic or renal disease</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>